Compare Dr. Reddys with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ALEMBIC LTD - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB ALEMBIC LTD DR. REDDYS LAB/
ALEMBIC LTD
 
P/E (TTM) x 22.3 73.7 30.3% View Chart
P/BV x 3.3 2.6 127.6% View Chart
Dividend Yield % 0.7 0.4 181.5%  

Financials

 DR. REDDYS LAB   ALEMBIC LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
ALEMBIC LTD
Mar-18
DR. REDDYS LAB/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs2,87572 3,993.1%   
Low Rs1,88834 5,569.3%   
Sales per share (Unadj.) Rs930.24.7 19,789.5%  
Earnings per share (Unadj.) Rs117.46.1 1,923.8%  
Cash flow per share (Unadj.) Rs185.86.2 2,974.3%  
Dividends per share (Unadj.) Rs20.000.20 10,000.0%  
Dividend yield (eoy) %0.80.4 222.3%  
Book value per share (Unadj.) Rs844.440.7 2,076.8%  
Shares outstanding (eoy) m166.07267.03 62.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.611.3 22.7%   
Avg P/E ratio x20.38.7 233.8%  
P/CF ratio (eoy) x12.88.5 151.2%  
Price / Book Value ratio x2.81.3 216.6%  
Dividend payout %17.03.3 519.8%   
Avg Mkt Cap Rs m395,49614,139 2,797.2%   
No. of employees `00022.0NA-   
Total wages/salary Rs m33,562207 16,182.3%   
Avg. sales/employee Rs Th7,032.8NM-  
Avg. wages/employee Rs Th1,527.9NM-  
Avg. net profit/employee Rs Th887.7NM-  
INCOME DATA
Net Sales Rs m154,4821,255 12,307.4%  
Other income Rs m3,375370 911.7%   
Total revenues Rs m157,8571,625 9,711.9%   
Gross profit Rs m31,782111 28,606.7%  
Depreciation Rs m11,34838 30,021.2%   
Interest Rs m8892 52,294.1%   
Profit before tax Rs m22,920442 5,187.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m4381,212 36.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,85824 16,108.6%   
Profit after tax Rs m19,5001,630 1,196.4%  
Gross profit margin %20.68.9 232.4%  
Effective tax rate %16.85.4 310.5%   
Net profit margin %12.6129.8 9.7%  
BALANCE SHEET DATA
Current assets Rs m111,1011,867 5,950.5%   
Current liabilities Rs m58,973591 9,975.1%   
Net working cap to sales %33.7101.6 33.2%  
Current ratio x1.93.2 59.7%  
Inventory Days Days7994 84.2%  
Debtors Days Days9474 128.1%  
Net fixed assets Rs m101,2451,791 5,653.3%   
Share capital Rs m830534 155.4%   
"Free" reserves Rs m139,40610,324 1,350.4%   
Net worth Rs m140,23610,858 1,291.6%   
Long term debt Rs m22,00041 53,398.1%   
Total assets Rs m224,65611,591 1,938.3%  
Interest coverage x26.8260.9 10.3%   
Debt to equity ratio x0.20 4,134.3%  
Sales to assets ratio x0.70.1 635.0%   
Return on assets %9.114.1 64.5%  
Return on equity %13.915.0 92.6%  
Return on capital %14.915.2 98.4%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m88,67319 457,077.3%   
Fx outflow Rs m19,104264 7,241.3%   
Net fx Rs m69,569-244 -28,462.9%   
CASH FLOW
From Operations Rs m28,704236 12,173.0%  
From Investments Rs m-7,727-224 3,449.6%  
From Financial Activity Rs m-21,326-27 80,172.9%  
Net Cashflow Rs m-314-15 2,121.6%  

Share Holding

Indian Promoters % 25.5 64.0 39.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 0.2 2,700.0%  
FIIs % 35.3 9.7 363.9%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 26.1 58.6%  
Shareholders   75,885 54,701 138.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   NATCO PHARMA  PANACEA BIOTECH  CADILA HEALTHCARE  ABBOTT INDIA  PLETHICO PHARMA  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

ALEMBIC LTD Announces Quarterly Results (3QFY19); Net Profit Down 41.9% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 20, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - AJANTA PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS